A/prof Raj Patil

Biography

A/Prof Patil brings more than 20 years of academic and pharmaceutical experience in Ophthalmology. Before joining SERI he was VP, Advanced Ocular Delivery Systems at iVeena, a biotech startup involved in the development of nanoparticle based and AAV gene based therapy for targeted drug delivery for the treatment of macular degeneration and diabetic retinopathy. Prior to joining iVeena, Dr Patil worked at Alcon from 2004 to 2011 and at Novartis Institute of Biomedical Research from 2011 to 2013 as an Associate Director of Research and held number of roles including Head of Molecular Pharmacology, Glaucoma Research and most recently Head of Molecular Pharmacology, Retina Research. At Alcon/Novartis he was responsible for identification and validation of novel targets in the therapeutic areas of glaucoma, retina and allergy and inflammation programs and advancing several preclinical candidates to clinical development. Prior to Alcon, Dr Patil served as an Associate Professor of Ophthalmology, Cell Biology & Genetics at University of Nebraska Medical Centre, Omaha from 2001 to 2004 and as an Assistant Professor of Ophthalmology, Molecular Biology & Pharmacology at Washington University in St. Louis from 1992 to 2001. Dr Patil received his Ph.D. from National Chemical Laboratory/University of Pune, India and completed his postdoctoral training at the University of Michigan, Ann Arbor, MI. He is the recipient of Olga Keith Wiess Special Scholar Award from Research to Prevent Blindness Foundation and NIH Director’s New Innovator Award. Dr Patil has authored over hundred peer reviewed research articles including reviews, book chapters and 4 patents.

Research Interest

Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Ocular Gene Therapy, Ocular Physiology & Pharmacology, Aqueous Humor Dynamics, Neuroprotection, Glaucoma